- Joined
- Oct 6, 2014
- Messages
- 1,424 (0.38/day)
System Name | octo1 |
---|---|
Processor | dual Xeon 2687W ES |
Motherboard | Supermicro |
Cooling | dual Noctua NH-D14 |
Memory | generic ECC reg |
Video Card(s) | 2 HD7950 |
Storage | generic |
Case | Rosewill Thor |
http://www.worldcommunitygrid.org/forums/wcg/viewthread_thread,37500
Don't know the details yet but hopefully this will be a drug discovery project since a new vaccine is already going through testing - which will move to West Africa in the coming months.
The vaccine uses a chimp adenovirus that doesn't affect humans and spliced in some of the genetic code from Ebola - http://www.nlm.nih.gov/medlineplus/news/fullstory_149671.html
So I guess we'll have to see just what the project will be focusing on.
Don't know the details yet but hopefully this will be a drug discovery project since a new vaccine is already going through testing - which will move to West Africa in the coming months.
The vaccine uses a chimp adenovirus that doesn't affect humans and spliced in some of the genetic code from Ebola - http://www.nlm.nih.gov/medlineplus/news/fullstory_149671.html
But even if the vaccine works, not everyone will be able to get it presumably and there's also the chance that it may not be 100% effective. So having drugs that can deal with the virus would still be something worthwhile pursuing. And any antiviral developed would almost certainly have broader applications.The clinical trial enrolled volunteers aged 18 to 50. Ten volunteers received a low-dose injection of the vaccine, while another 10 received the same vaccine at a higher dose.
Within a day of vaccination, two people who got the higher dose developed a fever, which was "short-lived and easily handled," Fauci said.
"There were no real red flags when it comes to safety," he said.
At two weeks and four weeks following vaccination, the researchers tested the volunteers' blood to determine if anti-Ebola antibodies were generated. All 20 volunteers developed such antibodies within four weeks of receiving the vaccine, but antibody levels were higher in those who received the higher-dose vaccine.
"The results of the vaccine trial are promising and show that this particular vaccine is able to induce protective levels of immunity," said Dr. Amesh Adalja, a senior associate with the Center for Health Security at the University of Pittsburgh Medical Center. "The trial also begins to provide a basis for selecting the optimal dose needed to achieve protection against Ebola."
Two other phase I trials for the vaccine are ongoing in the United Kingdom and Mali, with results expected by year-end, the NIH said.
But based on the success of the Bethesda trial, researchers hope to begin delivering the experimental vaccine to people in Liberia and Sierra Leone within a couple of months, Fauci said.
So I guess we'll have to see just what the project will be focusing on.